Nebenwirkungen · Halaven
HALAVEN 0.44 mg/ml solution for injection · Abschnitt 4.8 · PDF-Seite 9
HOS-124178 · Präparat HOS-095809
Hepatotoxicity In some patients with normal/abnormal liver enzymes prior treatment with eribulin, increased levels of liver enzymes have been reported with initiation of eribulin treatment. Such elevations appeared to have occurred early with eribulin treatment in cycle 1 – 2 for the majority of these patients and whilst thought likely to be a phenomenon of adaptation to eribulin treatment by the liver and not a sign of significant liver toxicity in most patients, hepatotoxicity has also been reported.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-11T15:05:00Z · SHA-256 31249ef6210ad802092fdf0a12213640c232c7a0e17f9862972975afd370495d · Passage 3f230e732b9b1b884cfd57f9b3f6931059230fe6d77924d58af3c5dd320d6f4e · Zeichen 12585–13092 im Abschnitt